Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?" (MyaRESP)

May 4, 2026 updated by: Institut de Myologie, France
Individuals with MG (IwMG) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. Dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. Identifying the cause(s) of dyspnea in MG may assist in finding therapeutic strategies, reducing discomfort, improving QoL and potentially limiting respiratory deterioration and incidence of MG crisis.

Study Overview

Status

Recruiting

Conditions

Detailed Description

MYaResp is a prospective observational, cross-sectional study to evaluate dyspnea in adults with autoimmune myasthenia gravis.

Study aims include to:

  • Describe the characteristics of dyspnea in IwMG
  • Understand contributing factors and factors associated with dyspnea in IwMG including the relationship between patient-reported dyspnea, disease severity and functional limitations.
  • Determine the most effective tests to identify the causes and contributing factors of dyspnea

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Age ≥18 Confirmed diagnosis of autoimmune MG Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score

Description

Inclusion Criteria:

  • Age ≥18
  • Confirmed diagnosis of autoimmune MG
  • Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score
  • Signed consent form
  • Affiliated to or beneficiary of a social security scheme

Exclusion Criteria:

  • Known Pregnancy
  • Known respiratory disorder (other than MG)
  • Recent (within past 4 weeks) respiratory infection
  • Current MG crisis or exacerbation (necessitating increase in MG medication &/or hospital admission)
  • No dyspnea - score 0 or 3 on the respiration item on the MG- activities of daily living score
  • Severe cognitive impairment/guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dyspnea questionnaires
Time Frame: baseline
Dyspnea-12
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
cardiopulmonary exercise test
Time Frame: baseline
cycle ergometer
baseline
Polysomnography
Time Frame: baseline
evaluation of sleep disordered breathing
baseline
Functional measures
Time Frame: baseline
6 minute walk test
baseline
Quality of life questionnaires
Time Frame: baseline
Revised version of the myasthenia gravis quality of life questionnaire (Burns, French validation Birnbaum)
baseline
Anxiety and depression
Time Frame: baseline
Hospital Anxiety and Depression Scale
baseline

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
impact of myasthenia in daily living
Time Frame: baseline
impact of myasthenia in daily living score
baseline
Respiratory pressures
Time Frame: baseline
inspiratory and expiratory pressures
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut de Myologie, France

Collaborators

APHP

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 8, 2026

Primary Completion (Estimated)

June 1, 2028

Study Completion (Estimated)

June 1, 2028

Study Registration Dates

First Submitted

February 20, 2025

First Submitted That Met QC Criteria

March 4, 2025

First Posted (Actual)

March 10, 2025

Study Record Updates

Last Update Posted (Actual)

May 8, 2026

Last Update Submitted That Met QC Criteria

May 4, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MyaRESP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myasthenia Gravis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe